Moderna's post-pandemic vaccine demand is weak, with mRESVIA unlikely to gain significant RSV market share due to commoditization and entrenched competitors. Financials remain strained: high costs ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

When short-sellers (bears) bet heavily against companies on the S&P 500 (IVV), investors should not ignore them. Enphase ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

But its financial fortunes have reversed since then due to declining demand for COVID-19 shots and slow uptake for an RSV vaccine it’s also brought to market. Moderna has revised its revenue guidance ...

Moderna reported negligible mRESVIA (RSV vaccine) sales in the second quarter of 2025. Moderna’s RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries.

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

The American Academy of Pediatrics’ new vaccine schedule differs from government recommendations. Mr. Funk was the managing ...

The American Academy of Pediatrics is splitting from the federal government in its recommendations on which children should ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening bell. The company’s earnings beat estimates by 13.70% in the last reported ...